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ABSTRACT 29 
Long-chain acyl-CoA synthetase 4 (ACSL4) has a unique substrate specificity for arachidonic 30 
acid (AA). Hepatic ACSL4 is coregulated with the phospholipid remodeling enzyme 31 
lysophosphatidylcholine acyltransferase 3 (LPCAT3) by PPARδ to modulate plasma triglyceride 32 
metabolism. In this study, we investigated the acute effects of hepatic ACSL4 deficiency on lipid 33 
metabolism in adult mice fed a high-fat diet (HFD). Adenovirus-mediated expression of a mouse 34 
ACSL4 shRNA (Ad-shAcsl4) in the liver of HFD-fed mice led to a 43% reduction of hepatic 35 
arachidonoyl-CoA synthetase activity and a 53% decrease in ACSL4 protein levels as compared 36 
to mice receiving control adenovirus (Ad-shLacZ). Attenuated ACSL4 expression resulted in a 37 
substantial decrease in circulating VLDL-triglyceride levels without affecting plasma 38 
cholesterol. Lipidomics profiling revealed that knocking down ACSL4 altered liver phospholipid 39 
compositions, with the greatest impact on accumulation of abundant Lyso PC species LPC (16:0) 40 
and LPC (18:0), and lyso PE species LPE (16:0) and LPE (18:0). In addition, fasting glucose and 41 
insulin levels were higher in Ad-shAcsl4-transduced mice vs. control. Glucose tolerance testing 42 
further indicated an insulin-resistant phenotype upon knockdown of ACSL4. These results 43 
provide the first in vivo evidence that ACSL4 plays a role in plasma triglyceride and glucose 44 
metabolism and hepatic phospholipid synthesis of hyperlipidemic mice. 45 
46 
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 INTRODUCTION 47 
 The long chain acyl-CoA synthetase (ACSL) family consists of five enzymes (ACSL1, 48 
ACSL3, ACSL4, ACSL5 and ACSL6) that catalyze the formation of fatty acyl-CoAs from ATP, 49 
CoA, and long chain fatty acids (LCFAs) with certain degrees of substrate specificity (10-12, 35, 50 
48, 49). Because LCFA must be esterified to FA-CoA for entry into various metabolic pathways, 51 
including the cellular β-oxidation system responsible for FA oxidation (catabolism) and anabolic 52 
pathways for the synthesis of phospholipids (PLs), cholesterol esters (CEs), and triglycerides 53 
(TGs), ACSLs are considered rate determining enzymes in FA metabolism (14). It has been well 54 
recognized that, even though ACSL enzymes catalyze similar enzymatic reactions to esterify free 55 
FA (FFA) to acyl-CoA, they exhibit variable cellular functions and generate distinct metabolic 56 
outcomes in an isoform-specific and tissue/cell type-specific manner (2, 5, 28, 29, 36, 57). The 57 
current thinking is that substrate specificity, interacting proteins, subcellular localization, tissue 58 
specific expression, upstream signaling regulatory pathways and nutritional factors all contribute 59 
to the unique functions of individual ACSLs. 60 
 Within the ACSL family, ACSL4 is unique in that it has a marked substrate preference for 61 
polyunsaturated FA (PUFA), including arachidonic acid (AA), and plays an important role in 62 
AA cellular metabolism (18, 21, 23). In a feed forward fashion, AA regulates ACSL4 protein 63 
stability (17). ACSL4 is expressed in various tissues of humans and rodents, with the highest 64 
levels in brain, placenta, testis, ovary, spleen and adrenal cortex; low levels are detected in liver 65 
(3, 4). The expression of ACSL4 in normal liver tissue is relatively lower than that of ACSL1, 66 
the major ACSL isoform, but its expression is highly elevated in hepatocarcinoma (52) and 67 
nonalcoholic fatty liver disease (NAFLD) (22, 51, 56). Several in vitro studies have reported 68 
various functions of ACSL4 in channeling FA into different metabolic pathways. In rat smooth 69 
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muscle cells, altered ACSL4 expression was linked to PGE2 secretion (13). In pancreatic cell 70 
lines, ACSL4 participates in insulin secretion (1), and diminished ACSL4 expression was 71 
associated with reduced glucose-stimulated insulin secretion (20). Another study demonstrated 72 
the requirement of ACSL4 in TG-PUFA formation in activated hepatic stellate cells (55). In 73 
addition, studies in rat fibroblasts (26) and COS-7 cells (23) showed that exogenous 74 
overexpression of ACSL4 promotes AA incorporation into phosphatidylinositol (PI). A recent 75 
study using a novel mouse model of adipocyte-specific ablation of ACSL4 (Ad-KO) also 76 
observed reduced incorporation of AA into PLs of adipocytes derived from Ad-KO mice (19). 77 
These studies suggest that ACSL4 may be functionally involved in channeling PUFA into PL 78 
synthesis.  79 
 It has been demonstrated that the phospholipid remodeling enzyme lysophosphatidylcholine 80 
acyltransferase 3 (LPCAT3) is a critical determinant of TG secretion due to its unique ability to 81 
catalyze the incorporation of arachidonate into membranes, which impacts membrane lipid 82 
mobility in living cells (31, 39, 43, 54). LPCAT3 catalyzes the formation of 83 
phosphatidylcholines (PC) from saturated lysoPCs (LPC), inserting PUFAs at the sn-2 position 84 
(40, 42). Mice lacking LPCAT3 in the liver showed reduced plasma VLDL-TG levels and 85 
hepatosteatosis (31, 43). Interestingly, our previous studies have shown that ACSL4 and 86 
LPCAT3 are coordinately upregulated by the FA-activated nuclear receptor peroxisome 87 
proliferator-activated receptor δ (PPARδ) in liver cells (47). We demonstrated that treating mice 88 
with the PPARδ agonist L165041 increased hepatic ACSL4 and LPCAT3 expression, which was 89 
associated with increased incorporation of arachidonate into liver PC and 90 
phosphatidylethanolamine (PE). Collectively, it becomes clear that, despite all these previous 91 
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reports, the key metabolic function of ACSL4 in liver tissue under normal or disease conditions 92 
remains to be elucidated.  93 
 In the present study, we took the approach of adenovirus-mediated gene knockdown (KD) to 94 
examine the acute effects of hepatic ACSL4 deficiency on plasma and hepatic lipid metabolism 95 
in adult mice under a hyperlipidemic state. In view of the prominently altered metabolic features 96 
of ACSL4 KD mice, combined with lipidomic analysis, our studies for the first time reveal 97 
requirements of hepatic ACSL4 in supporting circulating TG levels and glucose metabolism, and 98 
in hepatic phospholipid synthesis. Whole genome transcriptomic analysis of liver tissues further 99 
identified p53 signaling pathways and genes involved in apoptosis being affected by ACSL4 100 
deficiency.  101 
MATERIALS AND METHODS 102 
Mice and diets  103 
 All animal studies were approved by the Institutional Animal Care and Use Committee at 104 
Veterans Affairs Palo Alto Health Care System (VAPAHCS) (Palo Alto, CA) and were 105 
consistent with the National Institutes of Health Guide for the Care and Use of Laboratory 106 
Animals. C57BL/6 male mice were purchased from The Jackson Laboratory (Bar Harbor, ME) 107 
and were fed a HFD (no. TD.88137 from Harlan; ~42% of total calories from fat; 0.15% 108 
cholesterol) for 8 weeks before adenoviral injections.  109 
Construction of Ad-shAcsl4 adenoviral vector for ACSL4 knockdown 110 
 A U6 promoter-based vector (pSH-ACSL4) that expresses shRNA targeting mouse ACSL4 111 
coding region (5’-GCTGCAAATGCCATGAAATTG-3’) was generated using Invitrogen’s 112 
BLOCK-iT™ U6 RNAi Entry Vector Kit following the manufacturer’s instructions. The 113 
sequence identity and orientation of ACSL4 shRNA in pSH-ACSL4 was confirmed by 114 
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sequencing. The pSH-ACSL4 plasmid was then recombined with pAD/BLOCK-iT DEST vector 115 
to generate Ad-shAcsl4 viral vector and transduced into HEK293A cells. The control adenovirus 116 
(Ad-shLacZ) targeting β-galactosidase coding region was constructed with the same procedure 117 
of Ad-shAcsl4. Both crude viral stocks were further amplified and purified by Vector Biolabs 118 
(Malvern, PA).  119 
Adenoviral transduction in mouse primary hepatocytes (MPH) 120 
 MPH seeded at 1x106 cells/well in 12 well plates were transduced with adenovirus 121 
expressing mouse Acsl4 shRNA (Ad-shAcsl4) or the control virus (Ad-shLacZ) at various 122 
multiplicity of infection (MOI) in 1 ml medium containing 0.5% FBS. After 5 h of infection, 123 
medium was replaced with fresh medium containing 10% FBS and cells were harvested 72 h 124 
post infection to isolate total RNA or cell lysates.  125 
Induction of hyperlipidemia in mice fed a HFD 126 
 In one pilot study, 8-10 weeks old male mice were fed a normal chow diet (NCD, n = 4) or a 127 
HFD (n = 4) for 8 weeks. Fasting serum and liver tissues were collected for lipid analysis. In 128 
addition, routine H. and E. staining was performed on formalin-fixed paraffin-embedded sections 129 
and Oil Red O staining on cryosections of liver tissue from NCD and HFD groups.  130 
Adenoviral infection in mice 131 
 In another study, male mice were fed a HFD for eight weeks. Continuing on the HFD, 12 132 
mice were divided into two groups with similar TC and TG levels. At day 0, mice were fully 133 
anesthetized and injected with Ad-shAcsl4 (6×109 pfu/per mouse) or an equal viral dose of a 134 
control adenovirus (Ad-shLacZ) via the retro-orbital sinus, as previously described (44, 47). 135 
Body weight and food intake were monitored throughout the duration of the experiment. After 136 
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11-days of infection, mice were fasted for 4 h (10AM to 2PM) before sacrificing for serum and 137 
liver tissue collections.  138 
Oral glucose tolerance test (OGTT) 139 
 OGTT was performed after 9 days of adenovirus injection. Mice were fasted overnight 140 
(approximately 16 hours; 5PM to 9AM) and were gavaged with glucose at a dose of 2 g/kg body 141 
weight. Blood glucose concentrations were measured using a glucometer at 0, 15, 30, 60, 90 and 142 
120 minutes post glucose administration. The area under the glucose concentration-time curve 143 
(glucose AUC 0-120min) was calculated using GraphPad Prism 7. 144 
Measurement of serum lipids   145 
 Serum was isolated at room temperature and stored at -80ºC.  Standard enzymatic methods 146 
were used to determine TC, TG, FFA and PL levels of serum using commercially available kits 147 
purchased from Stanbio Laboratory (Boerne, Texas, USA). Each sample was assayed in 148 
duplicate.  149 
Measurement of serum LTB4 150 
 Mouse  serum LTB4 concentration was determined by using the LTB4 enzyme immunoassay 151 
(EIA) kit (Cayman Chemical, Catalog # 520111) according to the manufacturer's protocol. 152 
HPLC separation of serum lipoprotein cholesterol and TGs 153 
 Fifty μl of serum samples obtained on day 11 after adenovirus injection from two animals of 154 
the same treatment group were pooled together, and a total of three pooled serum samples from 155 
Ad-shAcsl4 or Ad-shLacZ group were analyzed for cholesterol and TG levels of each of the 156 
major lipoprotein classes including chylomicron (CM, >80 nm), VLDL (30-80 nm), LDL (16-30 157 
nm), and HDL (8-16 nm) with a dual detection HPLC system consisting of two tandem 158 
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connected TSK gel Lipopropak XL columns (300 X 7.8-mm; Tosoh, Japan) at Skylight Biotech, 159 
Inc. (Tokyo, Japan) as described (9).   160 
Measurement of hepatic lipids 161 
Thirty mg of frozen liver tissue were homogenized in 1 ml chloroform/methanol (2:1) for lipid 162 
extraction (36). Total cholesterol and triglycerides were measured using kits from Stanbio 163 
Laboratory. 164 
Lipidomics 165 
 Fifty mg of individual frozen liver samples from Ad-shAcsl4 infected mice (n = 6) or control 166 
mice injected with Ad-shLacZ (n = 6) were subjected to lipidomic analysis at the West Coast 167 
Metabolic Center in the University of California at Davis. Six replicas of extracted lipids from 168 
each treatment group were applied in a lipidomics study using an automated electrospray 169 
ionization-tandem mass spectrometry (ESI-MS/MS) approach with a group of internal lipid 170 
standards. The LC/MS/MS analyses were carried out on an Agilent 1200 SL UHPLC system 171 
(Santa Clara, CA) coupled with AB Sciex 4000 QTRAP system (Foster City, CA) under negative 172 
MRM mode. The detailed methods were described previously (47). The specific peaks on the 173 
spectra are normalized and are relative semi-quantifications. All data acquisition, analysis, acyl 174 
group identification and normalization were conducted by the West Coast Metabolic Center of 175 
UC Davis.   176 
Real-time PCR 177 
 Total RNA isolation, generation of cDNA, and real-time quantitative PCR were conducted as 178 
previously reported (8). Each cDNA sample was assayed in duplicate. The correct size of the 179 
PCR product and the specificity of each primer pair were validated by examination of PCR 180 
products on an agarose gel. Primer sequences used in real-time PCR are listed in Table 1. Target 181 
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mRNA expression in each sample was normalized to the housekeeping gene GAPDH. The 2-ΔΔCt 182 
method was used to calculate relative mRNA expression levels. 183 
Western blot analysis 184 
 Approximately 50 mg of frozen liver was homogenized in RIPA buffer containing 1 mM 185 
PMSF and protease inhibitor cocktail (Roche) and phosphatase inhibitor cocktail (Sigma). After 186 
protein quantitation using BCA protein assay reagent (Pierce), 50 μg of homogenate proteins 187 
from individual samples were used in SDS-PAGE and Western blot analysis to determine 188 
relative protein levels of target proteins as described (45, 46). Table 2 lists all antibody technical 189 
information. Primary antibodies were used as 1:1000 dilution, and secondary antibodies were 190 
used at 1:10000 dilution. Immunoreactive bands of predicted molecular mass were visualized 191 
using a SuperSignal West Femto Maximum Sensitivity Substrate ECL kit from Thermo 192 
Scientific (Waltham, MA, USA) and quantified with Alpha View Software with normalization 193 
by signals of β-actin. 194 
Measurement of liver acyl-CoA synthetase activity  195 
 About 50 mg frozen liver tissue were dounce-homogenized 15 times in a buffer containing 196 
250 mM sucrose, 10 mM Tris, pH 7.4, 1 mM EDTA, 1 mM dithiothreitol (DTT), protease 197 
inhibitor cocktail (Roche) and phosphatase inhibitor cocktail (Sigma). Homogenates were 198 
centrifuged at 16,000 X g for 30 min at 4°C. Protein concentrations in supernatants were 199 
determined by BCA assay, and aliquots were stored at -80°C. Initial rates of total ACSL activity 200 
in liver homogenates were measured using 4 µg of liver homogenates at 37°C in the presence of 201 
175 mM Tris (pH 7.4), 8 mM MgCl2, 5 mM DTT, 10 mM ATP, 250 µM CoA, 50 µM [3H]AA, 202 
[3H]palmitic acid (PA),   or [3H]oleic acid (OA) in 0.5 mM Triton X-100, and 10 μM EDTA in a 203 
total volume of 0.1 mL. The reaction was initiated by adding the homogenized sample and 204 
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terminated by adding 1 ml Dole’s reagent as previously described (7). Generated [3H]AA-CoA,  205 
[3H]PA-CoA and [3H]OA-CoA were extracted, and the radioactivity was determined in a 206 
scintillation counter.  The radioactivity in a reaction that contained all components but omitted 207 
homogenate was included as a negative control. 208 
Microarray analysis 209 
 Microarray chip hybridization and data analysis were performed on individual livers of mice 210 
fed a HFD (n=4 per treatment group) at Boston University Microarray and Sequencing Resource 211 
Core Facility. Mouse Gene 2.0 ST CEL files were normalized to produce gene-level expression 212 
values using the implementation of the Robust Multiarray Average (RMA) in the affy package 213 
(version 1.36.1) included in the Bioconductor software suite (version 2.11) and an Entrez Gene-214 
specific probe set mapping (17.0.0) from the Molecular and Behavioral Neuroscience Institute 215 
(Brainarray) at the University of Michigan. Differential expression was assessed using the 216 
moderated (empirical Bayesian) t test implemented in the limma package (version 3.14.4). 217 
Correction for multiple hypothesis testing was accomplished using the Benjamini-Hochberg false 218 
discovery rate (FDR). All microarray analyses were performed using the R environment for 219 
statistical computing (version 2.15.1). For comparative analysis, general linear models for 220 
microarray data were performed for probe sets present on the microarray to identify probe sets 221 
that were differentially expressed between Ad-shAcsl4 and Ad-shLacZ groups, based on 222 
moderated t-statistics. Probe sets with a 1.5-fold change and a P-value <0.05 were considered 223 
biologically significant.  224 
Gene Set Enrichment Analysis (GSEA)  225 
 GSEA (version 2.2.1) was used to identify biological terms, pathways and processes that are 226 
coordinately up- or down-regulated within each pairwise comparison. The Entrez Gene 227 
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identifiers of the human homologs of the genes interrogated by the array were ranked according 228 
to the moderated t statistic computed between Ad-shAcsl4 and Ad-shLacZ. Mouse genes with 229 
multiple human homologs (or vice versa) were removed prior to ranking, so that the ranked list 230 
represents only those human genes that match exactly one mouse gene. This ranked list was then 231 
used to perform pre-ranked GSEA analyses using the Entrez Gene versions of the Hallmark, 232 
Biocarta, KEGG, Reactome, Gene Ontology (GO), and transcription factor and microRNA motif 233 
gene sets obtained from the Molecular Signatures Database (MSigDB), version 6.0. 234 
Statistical analysis  235 
 MS Excel and GraphPad Prism 7 were used to calculate averages and standard errors, 236 
generate graphs, and preform statistical tests. All values are presented as mean ± SEM. Unpaired 237 
Student two-tailed t-test was used to compare two groups. Statistical significance is displayed as 238 
p < 0.05 (one asterisk), p < 0.01 (two asterisks) or p < 0.001 (three asterisks). 239 
 240 
  241 
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RESULTS 242 
Knocking down hepatic ACSL4 expression in adult mice by adenovirus infection 243 
 To identify specific functions of hepatic ACSL4 in adult mice, we employed shRNA 244 
technology to deplete hepatic ACSL4 using adenovirus expressing a mouse Acsl4 shRNA (Ad-245 
shAcsl4). Efficiency of the viral particle was first examined in MPH that were transduced with 246 
different MOIs of Ad-shAcsl4 or a shRNA control virus Ad-shLacZ for 3 days. Expression of 247 
Acsl4 shRNA caused a dose-dependent reduction in ACSL4 protein levels (Fig. 1A).  Real-time 248 
PCR analysis of all hepatic ACSL isoforms demonstrated that Ad-shAcsl4 at the highest MOI 249 
reduced Acsl4 mRNA by 95% without affecting mRNA expression of other ACSL isoforms 250 
(Fig. 1B). 251 
 To examine the hepatic function of ACSL4 under a hyperlipidemic condition, initially we 252 
conducted a pilot diet study of feeding male C57BL/6J mice either a chow diet (NCD) or a HFD 253 
for 8 weeks. Examination of liver tissues showed that, compared to chow-fed mice, HFD feeding 254 
induced hepatosteatosis, as evidenced by a 6.9-fold increase in liver TG content and a 2.5-fold 255 
increase in liver cholesterol content; serum cholesterol levels were increased 1.7-fold by HFD 256 
feeding (Fig. 2A). Oil red-O staining of frozen liver sections (Fig. 2B) revealed large lipid 257 
droplets in livers of the HFD group that were not detected in livers from the chow diet group.  258 
Hepatic gene expression analysis by qRT-PCR showed that mRNA levels of inflammatory 259 
related gene IL1β and fibrosis-related genes α-smooth muscle actin (α-SMA) and collagen type I 260 
mRNA were all elevated in the HFD group compared to the control group (Fig. 2C).  261 
 Having established a hyperlipidemic mouse model and confirmed the specificity and efficacy 262 
of Ad-shAcsl4 in MPH, Ad-shAcsl4 or control virus (Ad-shLacZ) was injected into male mice 263 
fed the HFD for 8 weeks. Analysis of liver tissues of mice sacrificed on day 11 after viral 264 
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injection showed that transduction of Ad-shAcsl4 resulted in 53% depletion of ACSL4 protein 265 
(p<0.001, Fig. 3A), and Acsl4 mRNA levels were reduced by 64% (p<0.001). Levels of Acsl5 266 
and Acsl3 mRNAs were unchanged, while Acsl1 mRNA levels were increased by 18% (p<0.05) 267 
(Fig. 3B). In addition, mRNA levels of Lpcat3 were similar between the two groups. 268 
Measurements of total ACSL activity in liver homogenates in the presence of three different 3H-269 
labeled FA substrates (Fig. 3C) demonstrated that the arachidonoyl-CoA synthetase activity in 270 
the Ad-shAcsl4 group was markedly reduced by 43% (p<0.001) as compared to the control 271 
group, whereas oleoyl-CoA synthetase activities did not differ between the two groups. 272 
Interestingly, the palmitoyl-CoA synthetase activity in the Ad-shAcsl4 group was increased by 273 
15% (p<0.01) as compared to the control group, which is consistent with the increased Acsl1 274 
mRNA expression in the ACSL4 KD group.  Altogether, these results demonstrate the high 275 
efficacy and specificity of Ad-shAcsl4 in depleting ACSL4 in mouse liver cells.  276 
 277 
Ad-shAcsl4 mice fed a HFD had altered VLDL-TG and FFA metabolism 278 
 The body weight, liver weight, epididymal white adipose tissue mass and food intake did not 279 
differ between the two groups of mice injected with Ad-shAcsl4 or Ad-shLacZ (Fig. 4). 280 
Measurements of serum lipid levels showed that the transient knockdown of liver ACSL4 did not 281 
affect circulating levels of total cholesterol or PL, but significantly lowered serum TG levels by 282 
36% (p<0.01) and reduced serum FFA abundance by 31% (p<0.001) as compared to the control 283 
group (Fig. 5A-D). HPLC analysis of lipoprotein triglyceride and cholesterol profiles of serum 284 
samples from the Ad-shAcsl4 and control groups revealed that the reduction of TG was primarily 285 
caused by a substantial decrease in the VLDL fraction (Fig. 5E, F), whereas lipoprotein-286 
cholesterol fractions (Fig. 5G, H) only showed a small decrease in VLDL-cholesterol in hepatic 287 
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ACSL4 deficient mice, which is consistent with an overall lack of effects of ACSL4 knockdown 288 
on serum cholesterol levels in hyperlipidemic mice.  289 
 Next, we extracted hepatic lipids from livers of mice infected with Ad-shAcsl4 or Ad-290 
shLacZ. ACSL4 depletion led to a 20% increase in hepatic NEFA (FFA) levels without effects 291 
on hepatic cholesterol, TG or PL (Fig. 6A-D). Altogether, these results reveal a function of 292 
hepatic ACSL4 in modulating plasma VLDL-TG metabolism in mice fed a HFD.  293 
 294 
Knocking down ACSL4 generated an insulin-resistant phenotype 295 
 In addition to changes in serum TG and FFA levels, we observed that ACSL4 KD mice fed a 296 
HFD exhibited modest elevations in fasting serum glucose and insulin levels compared to HFD 297 
fed control mice (Fig. 7A, B). Glucose tolerance testing (GTT) further indicated a greater degree 298 
of glucose intolerance, with a 26% increase in the area under the curve (AUC) of serum glucose 299 
during the GTT, thereby leading to a higher score of HOMA-IR (homeostatic model assessment 300 
to determine insulin resistance) in hepatic ACSL4 KD mice compared to control mice (Fig. 7C-301 
E). 302 
 303 
Saturated LysoPC and LysoPE species selectively accumulated in ACSL4-depleted liver  304 
 Previous studies have shown that reduced incorporation of arachidonate at the sn-2 position 305 
of PC due to deficiency of LPCAT3 resulted in reduced plasma VLDL-TG concentrations (43), 306 
an observation similar to the reduced VLDL-TG phenotype in ACSL4 KD mice. Thus, we 307 
performed lipidomics analysis to profile PL molecular species in liver tissues of ACSL4 KD 308 
mice (Ad-shAcsl4) and control mice (Ad-shLacZ). Fig. 8A shows that LPC (16:0) was the most 309 
abundant LPC species in liver tissue, and its level was increased by ~ 45% (p<0.001) in Ad-310 
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shAcsl4 transduced mice. We also detected significant enrichment of three other LPC species. 311 
Furthermore, levels of LPE species 18:0 and 16:0 were increased 80% (p<0.001) and 70% 312 
(p<0.001), respectively, of control by knockdown of ACSL4 (Fig. 8B). Accumulations of 313 
saturated LPC and LPE are in line with reduced AA-CoA synthetase activity in ACSL4 depleted 314 
liver tissue (Fig. 3C) and support the role of ACSL4 in hepatic PL synthesis. Ablation of 315 
LPCAT3 in the liver of mice fed a Western diet was previously shown to significantly increase 316 
PC (34:1) abundance (43). Interestingly, we detected a 34% increase (p<0.001) of this PC 317 
species in ACSL4 depleted liver compared to control despite unchanged levels of abundant PC 318 
and PE species containing arachidonates (Fig. 8C, D). In addition, the ceramide species (d42:1) 319 
was increased by 36% by ACSL4 depletion (Fig. 8E), and no significant changes were observed 320 
in PI species between the two groups (Fig. 8F). Altogether, these results indicate that attenuated 321 
ACSL4 activity in the liver of HFD fed mice resulted in accumulation of saturated LysoPC and 322 
LysoPE, which could account, at least in part, for the reduced plasma VLDL abundance owing to 323 
the insufficient supply of arachidonate substrates to LPCAT3.  324 
 325 
Changes of lipogenic and oxidative pathways by ACSL4 depletion 326 
 To further understand the above observed complex changes in plasma TG, glucose, FFA and 327 
hepatic lipid levels, we examined the expression of genes involved in FA synthesis and β-328 
oxidation. QRT-PCR analysis revealed that hepatic expression of SREBP1c and its target genes 329 
encoding lipogenic enzymes Fas, Scd1 and Dgat2 were increased in ACSL4-deficient livers (Fig. 330 
9A). Western blot analysis using anti-FASN and anti-SCD1 antibodies further demonstrated the 331 
increased protein expression in liver homogenates of Ad-shAcsl4 mice (Fig. 9B). Measurement 332 
of a panel of FA-oxidative genes revealed increased expression of PPARα and its target genes 333 
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CPT1α and AcoX1, whereas PPARδ and PPARγ mRNA levels were unchanged (Fig. 9C). 334 
Increased expression of CPT1α protein in ACSL4 KD liver was also confirmed by Western 335 
blotting (Fig. 9D). Thus, these data suggest that ACSL4 deficiency increased both the synthesis 336 
and degradation of fatty acids, thus resulting in a slightly increased hepatic FFA content without 337 
substantial changes in hepatic TG abundance in mice in the context of a HFD feeding. Since 338 
ACSL1 is a direct target gene of PPARα (53), increases in ACSL1 mRNA level and palmitoyl-339 
CoA activity are likely the result of increased PPARα activity in ACSL4 KD mice. We also 340 
noticed that PPARδ expression is unchanged, which is consistent with the lack of effect of 341 
ACSL4 KD on Lpcat3 mRNA levels. 342 
 343 
ACSL4 knockdown protects from HFD-associated inflammatory mediator production and 344 
p53 activation  345 
 It is known that free AA can be metabolized by cyclooxygenases, lipoxygenase and 346 
cytochrome p450 enzyme systems into lipid mediators, producing inflammatory eicosanoids 347 
(PGE2, PGF2α, TXB2 and LTB4) (38, 41, 50). Furthermore, studies conducted in extrahepatic cell 348 
types have shown that suppression of ACSL4 activity or siRNA-mediated knockdown of ACSL4 349 
expression enhanced IL-1β-dependent production of prostaglandin (13, 25, 26, 34). Thus, we 350 
initially postulated that hepatic ACSL4 KD would increase liver inflammatory mediator 351 
production due to potentially altered AA metabolite profiles in the liver. Utilizing qRT-PCR, we 352 
measured mRNA levels of a panel of inflammatory genes TNFα, IL1β, IL6, CCL2 (chemokine 353 
(C-C motif) ligand 2) and Itgax (integrin alpha X) and, surprisingly, found that their mRNA 354 
levels were significantly lower in ACSL4 KD mice than those of control mice on a HFD (Fig. 355 
10A, left panel). In addition, ACSL4 KD also attenuated the expression of stress marker genes 356 
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Atf4 (activating transcription factor 4), Chop (C/EBP homolog protein) and Xbp1 (Fig. 10A, 357 
middle panel) and a panel of fibrotic genes (Fig. 10A, right panel). Analysis of liver 358 
homogenates for stress-induced JNK kinase further showed that the HFD-induced 359 
phosphorylation and activation of JNK was greatly attenuated by knocking down hepatic ACSL4 360 
(Fig. 10B).  Moreover, measurement of serum LTB4 showed a 51.6% (p<0.01) reduction of this 361 
inflammatory eicosanoid in ACSL4 KD mice on a HFD (Fig. 10C). Further analysis of liver 362 
histology and Oil Red O staining did not reveal overall histological differences in either fatty 363 
change or inflammation between liver tissue samples of 6 ACSL4 knockdown and 6 LacZ 364 
control animals fed a HFD, possibly because changes in gene expression occurred earlier than 365 
histological changes of fatty liver (data not shown). 366 
 It was recently reported that ablation of ACSL4 in adipose tissue of HFD fed mice is 367 
associated with protection against HFD-induced p53 activation and its downstream effects on 368 
inflammation (19). To determine whether the reduced inflammatory mediator production 369 
observed in Ad-shAcsl4 mice is associated with diminished p53 activation, we performed 370 
Western blot analysis to examine p53 protein expression in liver samples of Ad-shAcsl4 and Ad-371 
shLacZ mice. The results showed a substantial reduction of p53 protein levels in the ACS4 KD 372 
group (Fig. 11A). By contrast, LDL receptor (LDLR) protein levels were similar between the 373 
two groups, which correlates with the lack of effect of ACSL4 KD on plasma and hepatic 374 
cholesterol levels.  375 
 To further understand the impact of ACSL4 KD on p53, as well as p53-mediated 376 
downstream events, we carried out gene expression profiling of individual livers of HFD fed 377 
mice infected with Ad-shAcsl4 or control Ad-shLacZ. Using a cut off criterion of 1.5-fold 378 
change and a p value of <0.05, we identified 1164 genes that were downregulated and 416 genes 379 
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that were upregulated by ACSL4 deficiency. Importantly, GSEA KEGG pathway analysis 380 
revealed that the p53 signaling pathway was the third most enriched biological pathways 381 
downregulated following depletion of ACSL4. Eighteen genes within this gene set were 382 
significantly repressed (Fig. 11B). The well-known p53 target genes p21 (CDKN1A) and cyclin 383 
G1 were reduced by 9.3-fold (p<0.0001) and 3.5-fold (p<0.0001), respectively. Reduction of p21 384 
protein levels in Ad-shAcsl4 mice was further shown by Western blotting with anti-p21 antibody 385 
(Fig. 11A). Consequentially, the p53 activated apoptosis signaling pathway was attenuated in the 386 
liver of ACSL4 KD group as compared to control mice on a HFD (Fig. 11C). These microarray 387 
results were further validated by qRT-PCR analysis (Fig. 11D). Taken together, these results 388 
suggest that, in the context of HFD fed mice, similar to ablation of adipocyte ACSL4, knocking 389 
down hepatic ACSL4 results in protection of HFD-induced p53 activation and its downstream 390 
proinflammatory response.  391 
 392 
DISCUSSION 393 
 ACSL4 is an ACSL family member that has a key role in AA metabolism. Within this 394 
family, ACSL4 is the prominent isoform showing elevated expression in hepatocarcinoma (52) 395 
and NAFLD (22, 51, 56), both of which exhibit abnormal hepatic lipid metabolism. Our previous 396 
studies showed that ACSL4 expression and AA-CoA synthetase activity were upregulated in 397 
liver tissue of hyperlipidemic hamsters via a PPARδ-mediated mechanism (16). We also 398 
demonstrated that ACSL4 was co-regulated with Lpcat3 in the liver of mice by activation of 399 
PPARδ to modulate plasma TG metabolism (47). However, until the present study, no reports in 400 
the literature have addressed the specific roles played by hepatic ACSL4 in lipid metabolism in 401 
any live animal models. By employing a knockdown approach, the aim of this current study was 402 
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to directly assess the function of hepatic ACSL4 in hyperlipidemic adult mice, which display the 403 
pathological condition of NAFLD. Our study results revealed for the first time that hepatic 404 
ACSL4 is required for metabolism of plasma VLDL-TG and glucose, and for PL synthesis in the 405 
liver of mice in the context of HFD feeding.  406 
 We first demonstrated that adenovirus mediated expression of Acsl4 shRNA led to efficient 407 
and specific depletion of Acsl4 mRNA and protein in cultured MPH in vitro and in the liver of 408 
mice fed a HFD. Using three different 3H-labeled FA substrates, we further showed that ACSL4 409 
KD in mice reduced AA-CoA synthetase activity to a level nearly half of control without any 410 
attenuation of fatty-CoA synthetase activities using saturated (PA) or monounsaturated (OA) 411 
LCFA as substrates in liver tissue, which provided in vivo evidence for ACSL4’s preference for 412 
arachidonate as substrate. 413 
 One important finding of this current study is that hepatic ACSL4 KD reduced serum VLDL-414 
TG without any effects on plasma and hepatic cholesterol levels, thereby suggesting that ACSL4 415 
may direct PUFA into cellular TG pathways. The similar LDLR expression in liver tissues of 416 
Ad-shLacZ and Ad-shAcsl4 also suggests that cholesterol homeostasis is undisturbed by ACSL4 417 
KD in HFD fed mice.   418 
 One potential mechanism underlying the reduction of VLDL-TG may be related to the 419 
attenuation of hepatic LPCAT3 activity. Previous studies by other investigators have 420 
demonstrated that Lpcat3-dependent production of arachidonoyl phospholipids is a key 421 
determinant of TG secretion (43, 54). Genetic deletion of the Lpcat3 gene in the liver led to 422 
reduced plasma VLDL-TG and increased liver fat content. In our ACSL4 KD mice, the reduction 423 
of AA-CoA activity and substantial increases in saturated LysoPC and LysoPE species are 424 
indicative of reduced Lpcat3 activity. However, since ACSL4 KD did not alter Lpcat3 mRNA 425 
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expression, it is probable that decreased activity was due to diminished precursor substrates in 426 
the setting of ACSL4 KD. This was accompanied by lower plasma TG in the absence of notable 427 
changes in liver TG content. It is plausible that the partial depletion of hepatic ACSL4 and a 428 
relatively short period of knockdown diminished the impact of deficiency in the pool of hepatic 429 
arachidonate-CoA substrates on LPCAT3 activity. The lack of accumulation of hepatic TG could 430 
also be explained by the observation of an increased FA β-oxidation pathway, as well as an 431 
elevated lipogenic pathway, that perhaps counteracted their individual effects on TG content in 432 
the ACSL4-depleted liver of HFD-fed mice.  433 
 The anti-inflammatory effect of hepatic ACSL4 depletion in mice on a HFD diet is an 434 
interesting new finding. We observed reduced expression of proinflammatory genes, including 435 
TNFα and IL-1β, and stress-inducible genes, such as Chop and ATF4, and fibrotic genes in 436 
ACSL4 KD mice compared to control mice receiving Ad-shLacZ. These changes in gene 437 
expression are corroborated by the marked reduction of p-JNK abundance in liver homogenates 438 
and the lower blood concentration of LTB4, a biomarker of inflammation. These observations 439 
seemingly contradict our previous thinking about the relationship between ACSL4 and 440 
inflammation status. In smooth muscle cells, siRNA mediated depletion of ACSL4 led to 441 
increases in PGE2 production (13); in fibroblast 3Y1 cells, suppression of ACSL4 enzymatic 442 
activity and reduction of ACSL4 protein expression both resulted in enhanced COX-2 pathway 443 
(26). However, recent studies in breast cancer cells suggested that ACSL4 is involved in 444 
ferroptosis since depletion of ACSL4 strongly protected against ferroptosis by blocking PUFA 445 
incorporation into phospholipids (6, 58). Thus, in the case of ferroptosis and our study, depletion 446 
of ACSL4 has a consistent protective effect.  447 
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 Regard anti-inflammation, a recent study of ACSL4 ablation in adipose tissue by Killion et al 448 
(29) provided a clue that pointed to the reduction of HFD-induced p53 activation as a possible 449 
underlying mechanism for the reduced inflammation. These authors further reported that the 450 
reduction of p53 in ACSL4 ablated adipocytes derived from Ad-KO mice fed HFD was 451 
associated with increased expression of glutathione-mediated detoxification gene expression. 452 
Similar to the findings of ACSL4 deficiency in adipocytes of mice fed a HFD, in our study, 453 
hepatic depletion of ACSL4 lowered the p53 protein abundance in liver homogenates of HFD-454 
fed mice as compared to that of HFD-fed control mice. This was accompanied by marked 455 
reduction of the p53 signaling pathway, which was revealed by whole genome transcriptomic 456 
analysis. However, the gene array data did not show significant changes in expression patterns of 457 
genes involved in detoxification or lipid peroxidation between Ad-shLacZ and Ad-shAcsl4 458 
groups. Nevertheless, the suppression of p53 activation likely accounts for the anti-inflammatory 459 
effect of hepatic ACSL4 KD in HFD-fed mice.  460 
 Lastly, the apparent insulin resistant phenotype observed in ACSL4 KD mice, which 461 
exhibited lower plasma TG and reduced hepatic inflammatory mediator production, is a puzzle. 462 
We observed modest increases in blood glucose and insulin levels in Ad-shAcsl4 mice compared 463 
to control mice. Our analysis of hepatic expression of genes involved in glucose metabolism by 464 
qRT-PCR and gene array pathway analysis did not identify obvious candidate genes responsible 465 
for the elevation of plasma glucose and insulin levels. However, ceramide and Lyso PCs have 466 
been linked to insulin resistance (15, 24, 30, 32, 33, 37); and their accumulations in the liver of 467 
Ad-shAcsl4 mice could provide a connection to the insulin resistant phenotype. Previous studies 468 
have shown that certain PC species produced by the liver are signaling molecules that can affect 469 
systemic insulin sensitivity (27).  Thus, it is possible that the insulin resistance in hepatic ACSL4 470 
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KD mice stems from the response of extrahepatic metabolic tissues, such as skeletal muscle or 471 
adipocytes, to altered lipid signaling molecules secreted from the liver. Further investigations are 472 
needed to identify the causal factor or specific lipid mediators responsible for the insulin 473 
resistance in ACSL4 KD mice on a HFD.  474 
 In summary, utilizing an adenoviral mediated gene knockdown approach, we have identified 475 
new functions of hepatic ACSL4 in plasma TG metabolism and glucose metabolism as well as in 476 
liver PL synthesis. Furthermore, we demonstrated an unexpected inverse relationship between 477 
p53 activation and ACSL4 expression in the liver of mice on a HFD. Altogether, our new 478 
findings from this first in vivo study of hepatic function of ACSL4 warrant further investigations 479 
to clearly define all ACSL4 channeled PUFA metabolic pathways in the liver under a normal 480 
physiologic and pathological conditions.  481 
 482 
ACKNOWLEDGEMENTS 483 
 This study was supported by the Department of Veterans Affairs (Office of Research and 484 
Development, Medical Research Service; I01 BX001419 to J. L. and I01 BX000398 to F.B.K.) 485 
and by a NIH grant R01AT006336-01A1 to J.L. and P30DK116074 (FBK).  486 
CONFLICT OF INTEREST 487 
 None of authors have a conflict of interest regarding this study. 488 
 489 
  490 
Downloaded from www.physiology.org/journal/ajpendo at Univ of Queensland (130.102.042.098) on April 7, 2019.
24 
 
REFERENCES 491 
 492 
1. Ansari IH, Longacre MJ, Stoker SW, Kendrick MA, O'Neill LM, Zitur LJ, 493 
Fernandez LA, Ntambi JM, and MacDonald MJ. Characterization of Acyl-CoA synthetase 494 
isoforms in pancreatic beta cells: Gene silencing shows participation of ACSL3 and ACSL4 in 495 
insulin secretion. Arch Biochem Biophys 618: 32-43, 2017. 496 
2. Askari B, Kanter JE, Sherrid AM, Golej DL, Bender AT, Liu J, Hsueh WA, Beavo 497 
JA, Coleman RA, and Bornfeldt KE. Rosiglitazone inhibits acyl-CoA synthetase activity and 498 
fatty acid partitioning to diacylglycerol and triacylglycerol via a peroxisome proliferator-499 
activated receptor-gamma-independent mechanism in human arterial smooth muscle cells and 500 
macrophages. Diabetes 56: 1143-1152, 2007. 501 
3. Cao Y, Murphy KJ, McIntyre TM, Zimmerman GA, and Prescott SM. Expression of 502 
fatty acid-CoA ligase 4 during development and in brain. FEBS Lett 467: 263-267, 2000. 503 
4. Cao Y, Traer E, Zimmerman GA, McIntyre TM, and Prescott SM. Cloning, 504 
expression, and chromosomal localization of human long-chain fatty acid-CoA ligase 4 505 
(FACL4). Genomics 49: 327-330, 1998. 506 
5. Coleman RA, Van Horn CG, and GonzalezBaro MR. Do acyl-coA synthetases 507 
regulate fatty acid entry into synthetic versus degradative pathways? J Nutr 132: 2123-2126, 508 
2002. 509 
6. Doll S, Proneth B, Tyurina YY, Panzilius E, Kobayashi S, Ingold I, Irmler M, 510 
Beckers J, Aichler M, Walch A, Prokisch H, Trumbach D, Mao G, Qu F, Bayir H, 511 
Fullekrug J, Scheel CH, Wurst W, Schick JA, Kagan VE, Angeli JP, and Conrad M. 512 
Downloaded from www.physiology.org/journal/ajpendo at Univ of Queensland (130.102.042.098) on April 7, 2019.
25 
 
ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat Chem Biol 13: 513 
91-98, 2017. 514 
7. Dong B, Kan CF, Singh AB, and Liu J. High-fructose diet downregulates long-chain 515 
acyl-CoA synthetase 3 expression in liver of hamsters via impairing LXR/RXR signaling 516 
pathway. J Lipid Res 54: 1241-1254, 2013. 517 
8. Dong B, Wu M, Li H, Kraemer FB, Adeli K, Seidah NG, Park SW, and Liu J. Strong 518 
induction of PCSK9 gene expression through HNF1alpha and SREBP2: mechanism for the 519 
resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters. J Lipid Res 51: 520 
1486-1495, 2010. 521 
9. Dong B, Young M, Liu X, Singh AB, and Liu J. Regulation of lipid metabolism by 522 
obeticholic acid in hyperlipidemic hamsters. J Lipid Res 58: 350-363, 2017. 523 
10. Ellis JM, Frahm JL, Li LO, and Coleman RA. Acyl-coenzyme A synthetases in 524 
metabolic control. Curr Opin Lipidol 21: 212-217, 2010. 525 
11. Ellis JM, Li LO, Wu PC, Koves TR, Ilkayeva O, Stevens RD, Watkins SM, Muoio 526 
DM, and Coleman RA. Adipose acyl-CoA synthetase-1 directs fatty acids toward beta-527 
oxidation and is required for cold thermogenesis. Cell Metab 12: 53-64, 2010. 528 
12. Ellis JM, Mentock SM, Depetrillo MA, Koves TR, Sen S, Watkins SM, Muoio DM, 529 
Cline GW, Taegtmeyer H, Shulman GI, Willis MS, and Coleman RA. Mouse cardiac acyl 530 
coenzyme a synthetase 1 deficiency impairs Fatty Acid oxidation and induces cardiac 531 
hypertrophy. Mol Cell Biol 31: 1252-1262, 2011. 532 
13. Golej DL, Askari B, Kramer F, Barnhart S, Vivekanandan-Giri A, Pennathur S, 533 
and Bornfeldt KE. Long-chain acyl-CoA synthetase 4 modulates prostaglandin E(2) release 534 
from human arterial smooth muscle cells. J Lipid Res 52: 782-793, 2011. 535 
Downloaded from www.physiology.org/journal/ajpendo at Univ of Queensland (130.102.042.098) on April 7, 2019.
26 
 
14. Grevengoed TJ, Klett EL, and Coleman RA. Acyl-CoA metabolism and partitioning. 536 
Annu Rev Nutr 34: 1-30, 2014. 537 
15. Ha CY, Kim JY, Paik JK, Kim OY, Paik YH, Lee EJ, and Lee JH. The association of 538 
specific metabolites of lipid metabolism with markers of oxidative stress, inflammation and 539 
arterial stiffness in men with newly diagnosed type 2 diabetes. Clin Endocrinol (Oxf) 76: 674-540 
682, 2012. 541 
16. Kan CF, Singh AB, Dong B, Shende VR, and Liu J. PPARdelta activation induces 542 
hepatic long-chain acyl-CoA synthetase 4 expression in vivo and in vitro. Biochim Biophys Acta 543 
1851: 577-587, 2015. 544 
17. Kan CF, Singh AB, Stafforini DM, Azhar S, and Liu J. Arachidonic acid 545 
downregulates acyl-CoA synthetase 4 expression by promoting its ubiquitination and 546 
proteasomal degradation. J Lipid Res 55: 1657-1667, 2014. 547 
18. Kang MJ, Fujino T, Sasano H, Minekura H, Yabuki N, Nagura H, Iijima H, and 548 
Yamamoto TT. A novel arachidonate-preferring acyl-CoA synthetase is present in steroidogenic 549 
cells of the rat adrenal, ovary, and testis. Proc Natl Acad Sci U S A 94: 2880-2884, 1997. 550 
19. Killion EA, Reeves AR, El Azzouny MA, Yan QW, Surujon D, Griffin JD, Bowman 551 
TA, Wang C, Matthan NR, Klett EL, Kong D, Newman JW, Han X, Lee MJ, Coleman RA, 552 
and Greenberg AS. A role for long-chain acyl-CoA synthetase-4 (ACSL4) in diet-induced 553 
phospholipid remodeling and obesity-associated adipocyte dysfunction. Mol Metab 9: 43-56, 554 
2018. 555 
20. Klett EL, Chen S, Edin ML, Li LO, Ilkayeva O, Zeldin DC, Newgard CB, and 556 
Coleman RA. Diminished Acyl-CoA Synthetase Isoform 4 Activity in INS 832/13 Cells 557 
Downloaded from www.physiology.org/journal/ajpendo at Univ of Queensland (130.102.042.098) on April 7, 2019.
27 
 
Reduces Cellular Epoxyeicosatrienoic Acid Levels and Results in Impaired Glucose-stimulated 558 
Insulin Secretion. J Biol Chem 288: 21618-21629, 2013. 559 
21. Klett EL, Chen S, Yechoor A, Lih FB, and Coleman RA. Long-chain acyl-CoA 560 
synthetase isoforms differ in preferences for eicosanoid species and long-chain fatty acids. J 561 
Lipid Res 58: 884-894, 2017. 562 
22. Kotronen A, Yki-Jarvinen H, Aminoff A, Bergholm R, Pietilainen KH, Westerbacka 563 
J, Talmud PJ, Humphries SE, Hamsten A, Isomaa B, Groop L, Orho-Melander M, 564 
Ehrenborg E, and Fisher RM. Genetic variation in the ADIPOR2 gene is associated with liver 565 
fat content and its surrogate markers in three independent cohorts. Eur J Endocrinol 160: 593-566 
602, 2009. 567 
23. Kuch EM, Vellaramkalayil R, Zhang I, Lehnen D, Brugger B, Sreemmel W, Ehehalt 568 
R, Poppelreuther M, and Fullekrug J. Differentially localized acyl-CoA synthetase 4 569 
isoenzymes mediate the metabolic channeling of fatty acids towards phosphatidylinositol. 570 
Biochim Biophys Acta 1841: 227-239, 2014. 571 
24. Kurek K, Piotrowska DM, Wiesiolek-Kurek P, Lukaszuk B, Chabowski A, Gorski 572 
J, and Zendzian-Piotrowska M. Inhibition of ceramide de novo synthesis reduces liver lipid 573 
accumulation in rats with nonalcoholic fatty liver disease. Liver Int 34: 1074-1083, 2014. 574 
25. Kuwata H and Hara S. Inhibition of long-chain acyl-CoA synthetase 4 facilitates 575 
production of 5, 11-dihydroxyeicosatetraenoic acid via the cyclooxygenase-2 pathway. Biochem 576 
Biophys Res Commun 465: 528-533, 2015. 577 
26. Kuwata H, Yoshimura M, Sasaki Y, Yoda E, Nakatani Y, Kudo I, and Hara S. Role 578 
of long-chain acyl-coenzyme A synthetases in the regulation of arachidonic acid metabolism in 579 
interleukin 1beta-stimulated rat fibroblasts. Biochim Biophys Acta 1841: 44-53, 2014. 580 
Downloaded from www.physiology.org/journal/ajpendo at Univ of Queensland (130.102.042.098) on April 7, 2019.
28 
 
27. Lee JM, Lee YK, Mamrosh JL, Busby SA, Griffin PR, Pathak MC, Ortlund EA, 581 
and Moore DD. A nuclear-receptor-dependent phosphatidylcholine pathway with antidiabetic 582 
effects. Nature 474: 506-510, 2011. 583 
28. Lewin TM, Kim JH, Granger DA, Vance JE, and Coleman RA. Acyl-CoA synthetase 584 
isoforms 1, 4, and 5 are present in different subcellular membranes in rat liver and can be 585 
inhibited independently. J Biol Chem 276: 24674-24679, 2001. 586 
29. Li LO, Grevengoed TJ, Paul DS, Ilkayeva O, Koves TR, Pascual F, Newgard CB, 587 
Muoio DM, and Coleman RA. Compartmentalized acyl-CoA metabolism in skeletal muscle 588 
regulates systemic glucose homeostasis. Diabetes 64: 23-35, 2015. 589 
30. Li LO, Klett EL, and Coleman RA. Acyl-CoA synthesis, lipid metabolism and 590 
lipotoxicity. Biochim Biophys Acta 1801: 246-251, 2010. 591 
31. Li Z, Jiang H, Ding T, Lou C, Bui HH, Kuo MS, and Jiang XC. Deficiency in 592 
lysophosphatidylcholine acyltransferase 3 reduces plasma levels of lipids by reducing lipid 593 
absorption in mice. Gastroenterology 149: 1519-1529, 2015. 594 
32. Longato L, Tong M, Wands JR, and de la Monte SM. High fat diet induced hepatic 595 
steatosis and insulin resistance: Role of dysregulated ceramide metabolism. Hepatol Res 42: 412-596 
427, 2012. 597 
33. Lyn-Cook LE, Jr., Lawton M, Tong M, Silbermann E, Longato L, Jiao P, Mark P, 598 
Wands JR, Xu H, and de la Monte SM. Hepatic ceramide may mediate brain insulin resistance 599 
and neurodegeneration in type 2 diabetes and non-alcoholic steatohepatitis. J Alzheimers Dis 16: 600 
715-729, 2009. 601 
Downloaded from www.physiology.org/journal/ajpendo at Univ of Queensland (130.102.042.098) on April 7, 2019.
29 
 
34. Maloberti PM, Duarte AB, Orlando UD, Pasqualini ME, Solano AR, Lopez-Otin C, 602 
and Podesta EJ. Functional interaction between acyl-CoA synthetase 4, lipooxygenases and 603 
cyclooxygenase-2 in the aggressive phenotype of breast cancer cells. PLOS one 5: e15540, 2010. 604 
35. Mashek DG, Li LO, and Coleman RA. Rat long-chain acyl-CoA synthetase mRNA, 605 
protein, and activity vary in tissue distribution and in response to diet. J Lipid Res 47: 2004-606 
2010, 2006. 607 
36. Mashek DG, Li LO, and Coleman RA. Rat long-chain acyl-CoA synthetase mRNA, 608 
protein, and activity vary in tissue distribution and in response to diet. J Lipid Res 47: 2004-609 
2010, 2006. 610 
37. Motley ED, Kabir SM, Gardner CD, Eguchi K, Frank GD, Kuroki T, Ohba M, 611 
Yamakawa T, and Eguchi S. Lysophosphatidylcholine inhibits insulin-induced Akt activation 612 
through protein kinase C-alpha in vascular smooth muscle cells. Hypertension 39: 508-512, 613 
2002. 614 
38. Orlando UD, Garona J, Ripoll GV, Maloberti PM, Solano AR, Avagnina A, Gomez 615 
DE, Alonso DF, and Podesta EJ. The functional interaction between Acyl-CoA synthetase 4, 5-616 
lipooxygenase and cyclooxygenase-2 controls tumor growth: a novel therapeutic target. PLOS 617 
one 7: e40794, 2012. 618 
39. Paalvast Y, de Boer JF, and Groen AK. Developments in intestinal cholesterol 619 
transport and triglyceride absorption. Curr Opin Lipidol 28: 248-254, 2017. 620 
40. Pan X, Chen G, Kazachkov M, Greer MS, Caldo KM, Zou J, and Weselake RJ. In 621 
Vivo and in Vitro Evidence for Biochemical Coupling of Reactions Catalyzed by 622 
Lysophosphatidylcholine Acyltransferase and Diacylglycerol Acyltransferase. J Biol Chem 290: 623 
18068-18078, 2015. 624 
Downloaded from www.physiology.org/journal/ajpendo at Univ of Queensland (130.102.042.098) on April 7, 2019.
30 
 
41. Perez-Chacon G, Astudillo AM, Balgoma D, Balboa MA, and Balsinde J. Control of 625 
free arachidonic acid levels by phospholipases A2 and lysophospholipid acyltransferases. 626 
Biochim Biophys Acta 1791: 1103-1113, 2009. 627 
42. Perez-Chacon G, Astudillo AM, Ruiperez V, Balboa MA, and Balsinde J. Signaling 628 
role for lysophosphatidylcholine acyltransferase 3 in receptor-regulated arachidonic acid 629 
reacylation reactions in human monocytes. J Immunol 184: 1071-1078, 2010. 630 
43. Rong X, Wang B, Dunham MM, Hedde PN, Wong JS, Gratton E, Young SG, Ford 631 
DA, and Tontonoz P. Lpcat3-dependent production of arachidonoyl phospholipids is a key 632 
determinant of triglyceride secretion. Elife 4, 2015. 633 
44. Shende VR, Wu M, Singh AB, Dong B, Kan CF, and Liu J. Reduction of circulating 634 
PCSK9 and LDL-C levels by liver-specific knockdown of HNF1alpha in normolipidemic mice. J 635 
Lipid Res 56: 801-809, 2015. 636 
45. Singh AB, Kan CF, Dong B, and Liu J. SREBP2 Activation Induces Hepatic Long-637 
chain Acyl-CoA Synthetase 1 (ACSL1) Expression in Vivo and in Vitro through a Sterol 638 
Regulatory Element (SRE) Motif of the ACSL1 C-promoter. J Biol Chem 291: 5373-5384, 2016. 639 
46. Singh AB, Kan CF, Shende V, Dong B, and Liu J. A novel posttranscriptional 640 
mechanism for dietary cholesterol-mediated suppression of liver LDL receptor expression. J 641 
Lipid Res 55: 1397-1407, 2014. 642 
47. Singh AB and Liu J. Identification of Hepatic Lysophosphatidylcholine Acyltransferase 643 
3 as a Novel Target Gene Regulated by Peroxisome Proliferator-activated Receptor delta. J Biol 644 
Chem 292: 884-897, 2017. 645 
48. Soupene E, Dinh NP, Siliakus M, and Kuypers FA. Activity of the acyl-CoA 646 
synthetase ACSL6 isoforms: role of the fatty acid Gate-domains. BMC Biochem 11: 18, 2010. 647 
Downloaded from www.physiology.org/journal/ajpendo at Univ of Queensland (130.102.042.098) on April 7, 2019.
31 
 
49. Soupene E and Kuypers FA. Mammalian long-chain acyl-CoA synthetases. Exp Biol 648 
Med (Maywood ) 233: 507-521, 2008. 649 
50. Spector AA. Arachidonic acid cytochrome P450 epoxygenase pathway. J Lipid Res 50 650 
Suppl: S52-S56, 2009. 651 
51. Stepanova M, Hossain N, Afendy A, Perry K, Goodman ZD, Baranova A, and 652 
Younossi Z. Hepatic gene expression of Caucasian and African-American patients with obesity-653 
related non-alcoholic fatty liver disease. Obes Surg 20: 640-650, 2010. 654 
52. Sung YK, Hwang SY, Park MK, Bae HI, Kim WH, Kim JC, and Kim M. Fatty acid-655 
CoA ligase 4 is overexpressed in human hepatocellular carcinoma. Cancer Sci 94: 421-424, 656 
2003. 657 
53. Suzuki H, Watanabe M, Fujino T, and Yamamoto T. Multiple promoters in rat acyl-658 
CoA synthetase gene mediate differential expression of multiple transcripts with 5'-end 659 
heterogeneity. J Biol Chem 270: 9676-9682, 1995. 660 
54. Taniguchi K, Hikiji H, Okinaga T, Hashidate-Yoshida T, Shindou H, Ariyoshi W, 661 
Shimizu T, Tominaga K, and Nishihara T. Essential Role of Lysophosphatidylcholine 662 
Acyltransferase 3 in the Induction of Macrophage Polarization in PMA-Treated U937 Cells. J 663 
Cell Biochem 116: 2840-2848, 2015. 664 
55. Tuohetahuntila M, Spee B, Kruitwagen HS, Wubbolts R, Brouwers JF, van de Lest 665 
CH, Molenaar MR, Houweling M, Helms JB, and Vaandrager AB. Role of long-chain acyl-666 
CoA synthetase 4 in formation of polyunsaturated lipid species in hepatic stellate cells. Biochim 667 
Biophys Acta 1851: 220-230, 2015. 668 
56. Westerbacka J, Kolak M, Kiviluoto T, Arkkila P, Siren J, Hamsten A, Fisher RM, 669 
and Yki-Jarvinen H. Genes involved in fatty acid partitioning and binding, lipolysis, 670 
Downloaded from www.physiology.org/journal/ajpendo at Univ of Queensland (130.102.042.098) on April 7, 2019.
32 
 
monocyte/macrophage recruitment, and inflammation are overexpressed in the human fatty liver 671 
of insulin-resistant subjects. Diabetes 56: 2759-2765, 2007. 672 
57. Wu M, Liu H, Chen W, Fujimoto Y, and Liu J. Hepatic expression of long-chain acyl-673 
CoA synthetase 3 is upregulated in hyperlipidemic hamsters. Lipids 44: 989-998, 2009. 674 
58. Yuan H, Li X, Zhang X, Kang R, and Tang D. Identification of ACSL4 as a biomarker 675 
and contributor of ferroptosis. Biochem Biophys Res Commun 478: 1338-1343, 2016. 676 
 677 
 678 
  679 
Downloaded from www.physiology.org/journal/ajpendo at Univ of Queensland (130.102.042.098) on April 7, 2019.
33 
 
 680 
FIGURE LEGENDS 681 
Figure 1. Knockdown of hepatic ACSL4 in MPH by Ad-shAcsl4 transduction.  682 
 MPH seeded in 12-well cell culture plate were transduced with Ad-shLacZ or Ad-shAcsl4 at 683 
indicated MOIs of adenovirus for three days. Total cell lysates and total RNA were separately 684 
isolated.  685 
(A) Western blot analysis of ACSL4 protein using anti-ACSL4 rabbit antibodies. 686 
(B) Real-time PCR analysis of mRNA levels of all ACSL isoforms expressed in mouse liver 687 
cells.  688 
 689 
Figure 2. High-fat diet exposure increased hepatic steatosis and serum cholesterol and 690 
elevated mRNA levels of inflammation and fibrosis related genes in mice. 691 
 Male C57BL/6J mice were fed a NCD (n = 4) or a HFD (n = 4) for two months.    692 
(A) Hepatic lipid levels and serum TC levels were measured. *** p<0.001 compared to NCD 693 
mice. 694 
(B) Oil red-O staining of representative liver sections of chow and HFD fed mice. 695 
(C) QRT-PCR analysis of hepatic gene expression. 696 
 697 
Figure 3. Depletion of ACSL4 in the liver of HFD-fed mice.  698 
 Male C57BL/6J mice fed a HFD for 8 weeks were injected with Ad-shAcsl4 (n = 6) or Ad-699 
shLacZ (n = 6). Eleven days after adenoviral injection, mice were sacrificed and serum samples 700 
and livers were isolated at the termination of the experiment. All data are mean ± SEM of 6 liver 701 
samples per group.  702 
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(A) Western blot analysis of hepatic ACSL4 protein and β-actin levels in individual livers of Ad-703 
shAcsl4 or Ad-shLacZ injected mice. The protein abundance of ACSL4 was quantified with 704 
normalization with β-actin using Alpha View Software. Significance was determined by 705 
unpaired Student’s t-test. n = 6 mice per group. ** p < 0.01.  706 
(B) Real-time PCR was conducted to determine relative expression levels of ACSL isoform 707 
mRNAs after normalization with GAPDH mRNA levels. Significance was determined by 708 
unpaired Student’s t-test. n = 6 mice per group. ** p < 0.01. * p < 0.05. 709 
(C) Total ACSL enzymatic activity in liver tissue homogenates was measured using 4 µg of 710 
homogenate proteins at 37°C in the presence of [3H] labeled AA, [3H] labeled OA or [3H] 711 
labeled PA. Significance was determined by unpaired Student’s t-test. n = 6 mice per group.  712 
*** p < 0.001 and ** p < 0.01. 713 
 714 
Figure 5. Hepatic ACSL4 deficiency reduced plasma VLDL-TG and FFA.  715 
Eleven days after adenoviral injection, mice were fasted 4 h and then sacrificed for serum and 716 
liver sample collections. TG, FFA, TC and PL levels were measured. In A-D, significance was 717 
determined by unpaired Student’s t-test. n = 6 mice per group. ** p < 0.01, and *** p < 0.001. 718 
(A) Serum TC. 719 
(B) Serum PL. 720 
(C) Serum TG. 721 
(D) Serum FFA. 722 
(E-H) Serum samples from two animals of the same treatment group were pooled together and a 723 
total of three pooled serum samples from each group were analyzed for triglyceride (E, F) and 724 
cholesterol (G, H) distribution in HPLC-separated lipoprotein factions. n = 3, * p < 0.05. 725 
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 726 
Figure 6. Analysis of hepatic lipid contents in HFD-fed mice injected with Ad-shAcsl4 or 727 
Ad-shLacZ.  728 
 Lipids were extracted from individual livers of Ad-shAcsl4 and Ad-shLacZ injected mice 729 
and measured for NEFA (A), TG (B), TC (C) and PL (D). All data are mean ± SEM of 6 liver 730 
samples per group. 731 
 732 
Figure 7. Effects of hepatic ACSL4 deficiency on serum glucose and insulin level.  733 
(A-B) Eleven days after adenoviral injection, 4 h fasting serum samples of individual mice were 734 
measured for glucose and insulin levels. 735 
(C-E) Glucose tolerance test was performed at 9 days after injection of ad-shAcsl4 or Ad-736 
shLacZ adenovirus. Mice were fasted overnight before administration of glucose (2 g/kg body 737 
weight). In A-E, significance was determined by unpaired Student’s t-test. n = 6 mice per group. 738 
* p < 0.05, and ** p < 0.01. 739 
 740 
Figure 8. Knocking down hepatic ACSL4 increases saturated LysoPC (LPC) and LysoPE 741 
(LPE) species in mouse liver samples.  742 
 CSH-ESI QTOF MS/MS analysis of the abundance of LPC species (A), LPE species (B), PC 743 
species (C), PE species (D), Ceramide species (E) and PI species (F) in livers of HFD fed mice 744 
injected with Ad-shAcsl4 or Ad-shLacZ. Values are the mean ± SEM of six liver samples per 745 
group. *P < 0.05, *** P < 0.001, compared with the Ad-shLacZ group.  746 
 747 
Figure 9. Effects of ACSL4 KD on the FA lipogenic and oxidative pathways.   748 
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(A, C) qRT-PCR was conducted to determine relative expression levels of mRNAs of lipogenic 749 
genes (A) and genes involved in FA β-oxidation (C) after normalization with GAPDH mRNA 750 
levels. Significance was determined by unpaired Student’s t-test. n = 6 mice per group. * p < 751 
0.05, ** p < 0.01, and *** p < 0.001. 752 
(B, D) Western blot analysis of FASN and SCD1 (B), and CPT1α (D) and β-actin levels in 753 
individual livers of Ad-shAcsl4 or Ad-shLacZ injected mice. The protein abundance of target 754 
protein was quantified with normalization with β-actin using Alpha View Software. Significance 755 
was determined by unpaired Student’s t-test. n = 6 mice per group. *** p < 0.001.  756 
 757 
Figure 10. ACSL4 KD attenuated HFD-induced hepatic inflammatory and stress-induced 758 
gene mRNA levels. 759 
(A) Real-time PCR was conducted to determine relative expression levels of hepatic mRNAs of 760 
proinflammatory genes and stress-induced genes and fibrotic genes after normalization with 761 
GAPDH mRNA levels. Significance was determined by Student’s t-test. n = 6 mice per group. * 762 
p < 0.05 and ** p < 0.01, *** p < 0.001. 763 
(B) Western blot analysis of phosphorylated JNK and total JNK in liver homogenates of HFD-764 
fed mice with Ad-shAcsl4 or Ad-shLacZ infection.  765 
(C) Serum LBT4 concentrations were measured in serum samples of mice fed a HFD. 766 
Significance was determined by unpaired Student’s t-test. n = 6 mice per group. ** p < 0.01.  767 
   768 
Figure 11. Repression of HFD-induced p53 activation and downstream events. 769 
(A) Western blot analysis of p53, LDLR, p21 and GAPDH in liver homogenates of HFD-fed 770 
mice with Ad-shAcsl4 or Ad-shLacZ infection. 771 
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(B) Heatmap illustration of changes in gene expression of the KEGG p53 signaling pathway in 772 
livers of Ad-shAcsl4 injected mice (n=6) compared to Ad-shLacZ mice (n=6). Graph shows fold 773 
changes in all genes within the indicated pathway that have a p value <0.05 and a fold change 774 
>1.5.  775 
(C) Heatmap illustration of changes in expression of apoptotic genes. Graph shows fold changes 776 
in all genes within this gene set that have a p value <0.05 and a fold change >1.5.  777 
(D) Quantitative real-time PCR was perfmored to determine the relative mRNA expression 778 
levels of genes in the p53 signaling pathway after normalization with GAPDH mRNA levels to 779 
validate the gene array results. Significance was determined by Student’s t-test. n = 6 mice per 780 
group. * p < 0.05 and *** p < 0.001. 781 
  782 
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Table 1. List of mouse qPCR primer sequences 783 
Gene Forward primer Reverse primer 
Acsl1 ATCTGGTGGAACGAGGCAAG TCCTTTGGGGTTGCCTGTAG 
Acsl3 TCTTGCAAACAAAGCTGAAGGA GGTTGGAGGCTTCCCATCAA 
Acsl4 CTTCCTCTTAAGGCCGGGAC TGCCATAGCGTTTTTCTTAGATTT 
Acsl5 GGCCAAACAGAATGCACAGG GATGCAGATCTCGCCTTCGT 
Lpcat3 GGCCTCTCAATTGCTTATTTCA AGCACGACACATAGCAAGGA 
Pparα AGACACCCTCTCTCCAGCTT TTCGCCGAAAGAAGCCCTTA 
Pparδ CGGACCTGGGGATTAATGGG ATGGACTGCCTTTACCGTGG 
Pparγ TGTGAGACCAACAGCCTGAC CCGCTTCTTTCAAATCTTGTCTGT 
Cpt1α GGCCATCTGTGGGAGTATGT ACTGTAGCCTGGTGGGTTTG 
Acox1 GGGAGTGCTACGGGTTACATG CCGATATCCCCAACAGTGATG 
Apaf1 GGAATCAGCTTGAAGCATGGC CCCGCTTATGTCCTGCTCATTA 
Bax TGAAGACAGGGGCCTTTTTG AATTCGCCGGAGACACTCG 
Casp3 ATGGAGAACAACAAAACCTCAGT TTGCTCCCATGTATGGTCTTTAC 
P21 CCTGGTGATGTCCGACCTG CCATGAGCGCATCGCAATC 
Cyclin g1 ACAACTGACTCTCAGAAACTGC CATTATCATGGGCCGACTCAAT 
Il1β TGCCACCTTTTGACAGTGATG TGATGTGCTGCTGCGAGATT 
Tnfα ACTGAACTTCGGGGTGATCG CTTGGTGGTTTGCTACGACG 
Il-6 CACTTCACAAGTCGGAGGCT CTGCAAGTGCATCATCGTTGT 
Atf4 TGGCGAGTGTAAGGAGCTAGAAA TCTTCCCCCTTGCCTTACG 
Chop CTGGAAGCCTGGTATGAGGAT CAGGGTCAAGAGTAGTGAAGGT 
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Xbp1 GAATGGACACGCTGGATCCT GCCACCAGCCTTACTCCACTC 
Ccl2 TTAAAAACCTGGATCGGAACCAA GCATTAGCTTCAGATTTACGGGT 
Itgax CTGGATAGCCTTTCTTCTGCTG GCACACTGTGTCCGAACTCA 
Chrebp TGGGTGTTCAGCATCCTCATC CAGCCAGGCCAGTGAGGTCT 
Fasn GTGATAGCCGGTATGTCGGG TAGAGCCCAGCCTTCCATCT 
Scd1 CTGCAGGTTGTGCTAGATGGGATGG GCCTGGGGTCTTTGGTAAGTAGGC 
Dgat2 GGCTACGTTGGCTGGTAACT TCTTCAGGGTGACTGCGTTC 
Srebp1c CAAGGCCATCGACTACATCCG CACCACTTCGGGTTTCATGC 
α-SMA GTCCCAGACATCAGGGAGTAA TCGGATACTTCAGCGTCAGGA 
Col1a1 GCTCCTCTTAGGGGCCACT CCACGTCTCACCATTGGGG 
Gapdh ATGGTGAAGGTCGGTGTGAA ACTGGAACATGTAGACCATGTAGT 
Tgf-β GGTTCATGTCATGGATGGTGC TGACGTCACTGGAGTTGTACGG 
Mmp-2 TTCCCCCGCAAGCCCAAGTG GAGAAAAGCGCAGCGGAGTGACG 
Timp-1 GCATCTCTGGCATCTGGCATC GCGGTTCTGGGACTTGTGGGC 
 784 
Table 2. List of Antibodies 785 
Antibody Species Catalog No. Vendor 
ACSL4 Rabbit Dr. Stephen Prescott  
FASN Mouse Sc-55580 Santa Cruz
SCD Mouse Sc-14720 Santa Cruz
P-JNK Rabbit 4668 Cell Signaling
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T-JNK Rabbit 9252 Cell Signaling
LDLR Rabbit 3839-100 Bio-vision 
GAPDH Mouse AM4300 Invitrogen 
β-Actin Mouse A1978 Sigma 
p21 Mouse sc-817 Santa Cruz
p53 Mouse sc-126 Santa Cruz
Mttp Mouse ab20737 Abcam 
Cpt1α Mouse Ab128568 Abcam 
Anti-rabbit HRP-conjugate Rabbit 7074P2 Cell Signaling
Anti-mouse HRP-conjugate Mouse 7076P2 Cell Signaling
 786 
 787 
 788 
 789 
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